The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors

被引：8
|
作者：
Agboola, Foluso [1 ]
Rind, David M. [1 ]
Walton, Surrey M. [2 ]
Herron-Smith, Serina [1 ]
Quach, Danny [2 ]
Pearson, Steven D. [1 ]
机构：
[1] Inst Clin & Econ Review, Boston, MA 02109 USA
[2] Univ Illinois, Ctr Pharmacoepidemiol & Pharmacoecon Res, Chicago, IL USA
来源：
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2021年 / 27卷 / 05期
关键词：
RECOMBINANT FACTOR-VIII;
D O I：
10.18553/jmcp.2021.27.5.667
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：667 / 673
页数：7
相关论文
共 50 条
  • [1] Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
    Ozelo, M. C.
    Mahlangu, J.
    Pasi, K. J.
    Giermasz, A.
    Leavitt, A. D.
    Laffan, M.
    Symington, E.
    Quon, D., V
    Wang, J-D
    Peerlinck, K.
    Pipe, S. W.
    Madan, B.
    Key, N. S.
    Pierce, G. F.
    O'Mahony, B.
    Kaczmarek, R.
    Henshaw, J.
    Lawal, A.
    Jayaram, K.
    Huang, M.
    Yang, X.
    Wong, W. Y.
    Kim, B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (11): : 1013 - 1025
  • [2] Valoctocogene Roxaparvovec (Roctavian) - A Gene Therapy for Severe Hemophilia A
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1686): : 157 - 158
  • [3] Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A
    Oldenburg, Johannes
    Chambost, Herve
    Liu, Hai
    Hawes, Charles
    You, Xiaojun
    Yang, Xinqun
    Newman, Vanessa
    Robinson, Tara M.
    Hatswell, Anthony J.
    Hinds, David
    Santos, Sandra
    Ozelo, Margareth
    ADVANCES IN THERAPY, 2024, 41 (06) : 2267 - 2281
  • [4] Emicizumab for hemophilia A without inhibitors
    Cafuir, Lorraine
    Kruse-Jarres, Rebecca
    Mancuso, Maria Elisa
    Kempton, Christine L.
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (07) : 515 - 524
  • [5] COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS
    Olasupo, O.
    Matino, D.
    Iorio, A.
    Blackhouse, G.
    Xie, F.
    Tarride, J. E.
    VALUE IN HEALTH, 2022, 25 (07) : S428 - S428
  • [6] THE IMPACT OF A COST SAVINGS CAP ON THE COST EFFECTIVENESS OF VALOCTOCOGENE ROXAPARVOVEC FOR THE TREATMENT OF HEMOPHILIA A IN THE UNITED STATES
    Sarker, J.
    Tice, J. A.
    Herce-Hagiwara, B.
    Fahim, S. M.
    Chu, J.
    Agboola, F.
    Pearson, S.
    Rind, D. M.
    Walton, S. M.
    VALUE IN HEALTH, 2024, 27 (06) : S143 - S143
  • [7] Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A
    Mahlangu, J.
    Kaczmarek, R.
    von Drygalski, A.
    Shapiro, S.
    Chou, S. -C.
    Ozelo, M. C.
    Kenet, G.
    Peyvandi, F.
    Wang, M.
    Madan, B.
    Key, N. S.
    Laffan, M.
    Dunn, A. L.
    Mason, J.
    Quon, D. V.
    Symington, E.
    Leavitt, A. D.
    Oldenburg, J.
    Chambost, H.
    Reding, M. T.
    Jayaram, K.
    Yu, H.
    Mahajan, R.
    Chavele, K. -M.
    Reddy, D. B.
    Henshaw, J.
    Robinson, T. M.
    Wong, W. Y.
    Pipe, S. W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (08): : 694 - 705
  • [8] A SIMULATION STUDY TO PROVIDE GUIDANCE FOR INDIVIDUALS TRANSITIONING FROM EMICIZUMAB TO VALOCTOCOGENE ROXAPARVOVEC
    Agarwal, S.
    Hermans, C.
    Miesbach, W.
    Pipe, S.
    Sidonio, E., Jr.
    Osmond, D.
    Newman, W.
    Henshaw, J.
    Peyvandi, F.
    HAEMOPHILIA, 2023, 29 : 27 - 28
  • [9] Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A
    Madan, Bella
    Ozelo, Margareth C.
    Raheja, Priyanka
    Symington, Emily
    V. Quon, Doris
    Leavitt, Andrew D.
    Pipe, Steven W.
    Lowe, Gillian
    Kenet, Gili
    Reding, Mark T.
    Mason, Jane
    Wang, Michael
    von Drygalski, Annette
    Klamroth, Robert
    Shapiro, Susan
    Chambost, Herve
    Dunn, Amy L.
    Oldenburg, Johannes
    Chou, Sheng-Chieh
    Peyvandi, Flora
    Millar, Carolyn M.
    Osmond, Dane
    Yu, Hua
    Dashiell-Aje, Ebony
    Robinson, Tara M.
    Mahlangu, Johnny
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (07) : 1880 - 1893
  • [10] Cost-Effectiveness of Emicizumab for Prophylaxis in People with Severe Hemophilia A without Inhibitors
    Decker-Palmer, Marquita
    Lin, Chia-Wei
    Wilson, Michele
    McDade, Cheryl
    Bawa, Komal
    Kowal, Stacey
    Ravelo, Arliene
    Yu, Elaine
    Ko, Richard H.
    BLOOD, 2022, 140 : 13041 - 13042
12345